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Essentials
• Atrial fibrillation (AF) is common among patients with vascular disease.
• Studies on antithrombotic management in patients with AF and acute coronary syndrome (ACS) were assessed.
• Balancing the risk of ischemia and stroke and bleeding in patients with AF and ACS remains challenging.
• Direct oral anticoagulant–based management strategies are preferred.
1  | INTRODUC TION
Atrial fibrillation (AF) is the most common cardiac arrhythmia in 
adults, coexisting with vascular disease in about 30% of patients. 
Over 80% of patients with AF have ≥1 stroke risk factor(s), thus 
requiring stroke prevention therapy, most commonly using oral an-
ticoagulants (OACs).1 Given that the estimated global prevalence of 
AF is 1% to 3% and around 20% of patients with AF would need 
a percutaneous coronary intervention (PCI), about 1 to 3 million 
Europeans with AF taking OACs may require PCI.2‒5
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Abstract
Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) are at high 
risk of stroke, recurrent coronary ischemic events, and cardiovascular mortality. 
The composition of antithrombotic therapy including an oral anticoagulant and an-
tiplatelet drug(s) should be tailored according to the individual patient’s risk profile, 
to reduce the bleeding risk and maintain antithrombotic effect. There is no single 
antithrombotic treatment regimen that would fit to all patients with AF and ACS. 
However, available data promote the use of full-dose direct oral anticoagulants 
(DOACs) (dabigatran 150 mg twice daily or apixaban 5 mg twice daily) or rivaroxaban 
15 mg once daily in patients with AF and ACS or percutaneous coronary interven-
tion (PCI). For many patients, a DOAC plus P2Y12 inhibitor early after ACS and/or 
PCI would be optimal, whereas a longer course of triple therapy should be used in 
patients at high thrombotic risk.
K E Y W O R D S
acute coronary syndrome, antiplatelets, atrial fibrillation, oral anticoagulation, percutaneous 
coronary intervention, triple therapy
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Patients with AF and acute coronary syndrome (ACS) (ie, unsta-
ble angina, non–ST-segment elevation myocardial infarction [MI] or 
ST-segment elevation MI) have particularly high risk of recurrent 
coronary events (ie, MI or stent thrombosis), stroke, and cardiovas-
cular mortality.6
Preventing stroke, recurrent cardiac ischemia, and stent 
thrombosis using a combined antithrombotic therapy needs to be 
balanced against the risk of major bleeding (including intracranial 
hemorrhage ICH; Figure 1).1,7 The use of dual antiplatelet ther-
apy (DAPT) alone would not sufficiently protect patients against 
stroke, whereas OAC monotherapy, either a direct oral anticoag-
ulant (DOAC) or vitamin K antagonist (VKA), would not protect 
patients against new coronary events.8,9 Triple therapy (TT) using 
DAPT in combination with an OAC effectively prevents vascular 
ischemic events but is associated with considerably increased risk 
of bleeding.10
2  | OVERVIEW OF PUBLISHED DATA
Various studies have addressed the challenging management of pa-
tients with AF and ACS. Observational studies have shown that in AF 
patients after MI/PCI, dual antithrombotic therapy (clopidogrel and 
OAC) was equal to or better than TT in terms of benefit (MI or coronary 
death, fatal or nonfatal ischemic stroke, and all-cause mortality) and 
safety outcomes (fatal or nonfatal bleeding).11 In the Management of 
Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting 
(AFCAS) registry,12 TT, DAPT, and dual antithrombotic therapy (VKA 
with clopidogrel) had similar 1-year efficacy (stroke/transient ischemic 
events, peripheral embolism, MI, revascularization, definite/probable 
stent thrombosis) and safety (minor and major bleedings), but the study 
was limited by a low rate of adverse events and relatively small size of 
the group taking VKA with clopidogrel.
In the warfarin era, the What Is the Optimal Antiplatelet and 
Anticoagulant Therapy in Patients With Oral Anticoagulation and 
Coronary Stenting (WOEST) trial assessed the use of antiplatelet ther-
apy in patients on a VKA.13 The use of dual antithrombotic therapy 
(clopidogrel and a VKA) was compared to triple therapy (VKA and 
clopidogrel plus aspirin). Dual antithrombotic therapy was associated 
with significantly lower risk of Thrombolysis in Myocardial Infarction 
(TIMI) minor and major bleeding in comparison to TT (of note, there 
was no significant difference in major bleeds). However, the trial was 
small; not all patients were taking OACs for AF-related stroke preven-
tion (69% of patients had AF) and 25% to 30% of participants had an 
ACS; radial access was chosen in only 25% to 27% of patients; and TT 
was continued for 12 months. Notably, the WOEST trial also showed 
that patients taking TT had a higher risk of mortality compared with 
those on dual antithrombotic therapy (ie, clopidogrel and a VKA).
In the contemporary era of DOACs, post hoc analyses of the 
landmark DOACs trials for stroke prevention in AF showed consis-
tent efficacy and safety of the respective DOAC versus warfarin ir-
respective of the concomitant aspirin use or nonuse.14‒17 Although 
patients concomitantly using an antiplatelet drug (mostly aspirin) 
and OAC (either a DOAC or warfarin) were at higher risk of both 
ischemic and bleeding events compared with those on OAC mono-
therapy, the rates of hemorrhagic stroke or ICH were consistently 
lower with DOACs in comparison to warfarin.14‒17
Contemporary observational studies consistently reported find-
ings similar to those substudies. The Danish nationwide registry–based 
study, for example, reported that among patients with AF and MI and/
or PCI, those taking a DOAC plus DAPT had a significantly lower risk 
of bleeding than patients taking a VKA plus DAPT, with no significant 
differences in all-cause mortality, ischemic stroke, or MI between the 
2 treatment regimens.18 The study was limited by lack of significant pa-
rameters (International Normalized Ratio [INR], blood pressure, creati-
nine clearance, estimated glomerular filtration rate, and alanine amino 
transferase). There was also no possibility to compare safety and effi-
cacy of particular DOACs because of the limited number of patients.
Four recent open-label, randomized, controlled clinical trials inves-
tigated the use of DOACs in patients with AF with a recent ACS and/or 
undergoing a PCI19‒22 see Table 1. The PIONEER AF-PCI (an open-la-
bel, randomized, controlled, multicenter study exploring 2 treatment 
strategies of rivaroxaban and dose-adjusted oral VKA treatment strat-
egy in subjects with AF undergoing PCI)19 was an exploratory study 
comparing bleeding rates across 3 strategies (low-dose rivaroxaban 
[2.5 mg twice daily] plus DAPT vs. rivaroxaban 15 mg once daily, or 
10 mg once daily in patients with a creatinine clearance of <50 mL/
min, plus clopidogrel [dual antithrombotic therapy with DOAC or TT 
with DOAC] vs. TT with VKA plus DAPT) in patients with AF after a 
PCI with stent placement. The primary safety end point was defined 
as the percentage of patients with either TIMI major bleeding, minor 
bleeding, or bleeding requiring medical attention events by the end of 
12 months of randomized therapy. Secondary safety end points were 
defined as the incidence of each component of the bleeding composite 
(TIMI major bleeding, minor bleeding, and bleeding requiring medical 
attention), the composite of adverse cardiovascular events (cardiovas-
cular death, stroke, and MI), as well as cardiovascular death, MI, stroke, 
and stent thrombosis. The treatment regimens with rivaroxaban 15 mg 
once daily plus clopidogrel for 12 months or rivaroxaban 2.5 mg twice 
daily plus DAPT for 1, 6, or 12 months were associated with lower rates 
F I G U R E  1   Balancing the risks in the patients with atrial 
fibrillation who present with an acute coronary syndrome and/or 
undergo percutaneous coronary intervention/stenting
Increased 
risk of 
bleeding
THROMBOSIS
stroke,
recurrent 
myocardial 
ischemia,
stent thrombosis
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of the composite end point of bleeding than TT with VKA plus DAPT 
for 1, 6, or 12 months.23 All 3 strategies were associated with similar 
rates of composite outcome of cardiovascular mortality, MI, or stroke; 
however, the trial was underpowered to establish superiority or nonin-
feriority of evaluated strategies regarding these outcomes.
The aim of the Evaluation of Dual Therapy with Dabigatran 
Versus Triple Therapy With Warfarin in Patients With AF That 
Undergo a PCI With Stenting (REDUAL-PCI)20 was to compare 
dual antithrombotic therapy with dabigatran (dabigatran 150 mg 
or 110 mg twice daily plus clopidogrel or ticagrelor) to TT (warfa-
rin plus clopidogrel or ticagrelor plus aspirin) in patients with AF 
after PCI. The primary end point was defined as a major or clin-
ically relevant nonmajor (CRNM) bleeding event. The secondary 
end points were defined as a composite efficacy end point of MI, 
stroke, or systemic embolism; death or unplanned revasculariza-
tion; or a combined end point of thromboembolic events or death 
as well as the individual thromboembolic events and definite stent 
thrombosis. Compared with TT, both dual antithrombotic therapy 
regimens (ie, dabigatran 110 mg twice daily or 150 mg twice daily 
plus a P2Y12 inhibitor) were associated with significantly lower risk 
of major bleeding and CRNM bleeding. Dual antithrombotic ther-
apy with dabigatran (both dabigatran doses taken together) was 
noninferior to TT regarding the rates of MI, stroke, or systemic 
embolism. The study was underpowered to evaluate efficacy ac-
cording to dabigatran dose. Moreover, with respect to the results 
for the safety and efficacy end points, it is only possible to spec-
ulate on the relative contributions of the omission of aspirin and 
the type of OAC in the dual antithrombotic therapy groups and the 
triple-therapy group.
Both the PIONEER AF-PCI and RE-DUAL PCI trial clearly showed 
that dual therapy including the respective DOAC plus a P2Y12 inhib-
itor (mostly clopidogrel) was associated with significantly less major 
bleeding in comparison to TT with VKA plus dual antiplatelet ther-
apy. However, these trials could not distinguish whether the bleed-
ing risk reduction was driven by the use of a DOAC or nonuse of 
aspirin, or both.
Apixaban was tested in an open-label, 2 × 2 factorial, random-
ized controlled trial evaluating the safety of apixaban versus VKA 
and aspirin versus placebo in patients with AF and ACS and/or PCI 
(the AUGUSTUS trial).21 Patients with AF and an ACS and/or PCI 
within the preceding 14 days were randomized to apixaban 5 mg 
twice daily (or apixaban 2.5 mg twice daily in patients fulfilling 
dose reduction criteria) versus VKA and to aspirin versus aspi-
rin-placebo. The primary outcome was major bleeding defined by 
TA B L E  1   Randomized clinical trials of combined antithrombotic therapies in patients with AF with ACS or PCI/Stenting
 PIONEER-AF PCI 23 RE-DUAL PCI 20 ENTRUST-AF PCI 22 AUGUSTUS 24
Objective Rivaroxaban + P2Y12 inhibitor 
or DAPT versus VKA + DAPT 
in patients with NVAF 
undergoing PCI
Dabigatran + P2Y12 
inhibitor versus 
VKA + DAPT in 
patients with NVAF 
undergoing PCI
Edoxaban + P2Y12 inhibitor 
versus VKA + DAPT 
in patients with NVAF 
undergoing PCI
Apixaban + ASA/placebo 
versus VKA + ASA/placebo in 
patients with NVAF and ACS 
or PCI
Population size 2124 2725 1506 4600
Treatments Rivaroxaban 15 mg once 
daily + P2Y12 inhibitor,
rivaroxaban 2.5 mg once 
daily + P2Y12 inhibitor + ASA, 
then rivaroxaban 15 mg once 
daily + ASA,
VKA + P2Y12 inhibitor + ASA, 
then VKA + ASA
Dabigatran 120 mg 
or 110 mg twice 
daily + P2Y12 inhibitor,
VKA + P2Y12 
inhibitor + ASA
Edoxaban 60 mg once 
daily or 30 mg once 
daily + P2Y12 inhibitor,
VKA + P2Y12 
inhibitor + aspirin
Apixaban 5 mg or 2.5 mg twice 
daily + ASA/placebo
VKA + ASA/placebo
Duration 12 mo 6-30 mo 12 mo 6 mo
Primary 
outcome
Clinically significant bleeding Major or clinically 
relevant nonmajor 
bleeding event
Major or clinically relevant 
nonmajor bleeding
Major or clinically relevant 
nonmajor bleeding
Main secondary 
composite end 
point
The composite of death 
from cardiovascular causes, 
myocardial infarction, or 
stroke
The composite of 
thromboembolic 
events (myocardial 
infarction, stroke, or 
systemic embolism), 
death, or unplanned 
revascularization (PCI 
or coronary artery 
bypass grafting).
The composite of 
cardiovascular death, 
stroke, systemic embolic 
events, myocardial 
infarction, and definite 
stent thrombosis
The composite of death 
or hospitalization; the 
composite of death or 
ischemic events (stroke, 
myocardial infarction, 
stent thrombosis [definite 
or probable], or urgent 
revascularization)
Analysis period Treatment-emergent period Time to first event Day 1 to 12 mo Time to first event
Abbreviations: ACS, acute coronary syndrome; ASA, acetylsalicylic acid; DAPT, dual antiplatelet therapy; NVAF, nonvalvular atrial fibrillation; PCI, 
percutaneous coronary intervention; TTR, time in therapeutic range; VKA, vitamin K antagonists.
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the ISTH or CRNM bleeding. Secondary outcomes included the 
composite end point of death, stroke, MI, stent thrombosis, or ur-
gent hospitalization and the composite of death, hospitalization, 
and first hospitalization for any cause. Dual antithrombotic ther-
apy (apixaban plus P2Y12 inhibitor without aspirin) was associated 
with significantly lower incidence of bleeding when compared to 
regimen with VKA, aspirin, or both. Apixaban without aspirin was 
also correlated with significantly lower incidence of hospitaliza-
tions than VKA, aspirin, or both. There were no significant differ-
ences in ischemic events, although the rates of stent thrombosis 
and cardiovascular events were numerically higher in the place-
bo-treated patients compared to those on aspirin, while the rate of 
stroke was lower in patients on apixaban than in those on VKA.24 
One of the major study limitations is the poor quality of anticoag-
ulation with VKA (time in therapeutic range [TTR] in patients on 
VKA was lower than in previous randomized trials).
In the Safety and Efficacy of an Edoxaban-Based Antithrombotic 
Regimen in Patients With AF Following Successful PCI With Stent 
Placement (the ENTRUST-AF PCI) trial,22 AF patients undergoing PCI 
for stable coronary artery disease or ACS were randomized to dual 
antithrombotic therapy with a DOAC (edoxaban [60 mg once daily or 
30 mg once daily where dose reduction criteria were fulfilled] with 
a P2Y12 inhibitor for 12 months) or TT with VKA plus P2Y12 inhib-
itor and aspirin (100 mg once daily for 1-12 months). The primary 
end point was defined as the composite of major or CRNM bleeding 
defined by the ISTH. The composite of cardiovascular death, stroke, 
systemic embolic events, MI, and definite stent thrombosis was de-
fined as the main efficacy outcome. Edoxaban 60 mg once daily plus 
a P2Y12 inhibitor was noninferior to TT with VKA regarding major or 
CRNM bleeding events at 12 months. The main efficacy outcome 
(composite of cardiovascular death, stroke, systemic embolic events, 
MI, or definite stent thrombosis) were similar in both treatment 
arms. The study was limited by its open-label design. It was also un-
derpowered and limited by a small proportion of patients medicated 
with a more potent P2Y12 inhibitor than clopidogrel.
In a network meta-analysis that included the WOEST, PIONEER 
AF-PCI, RE-DUAL PCI, and AUGUSTUS trials and 4 different treat-
ment strategies (ie, DOAC or VKA plus a P2Y12 inhibitor dual reg-
imens and DOAC or VKA plus a P2Y12 and aspirin TT regimens),
25 
DOAC-based dual treatments were associated with fewer TIMI 
major bleedings and less ICH compared with VKA with DAPT, and 
there was no statistically significant difference in the rates of major 
adverse cardiac events, all-cause death, and cardiovascular mortality 
among the 4 treatment regimens. No statistically significant differ-
ences were revealed with respect to stroke, MI, and stent thrombo-
sis among the treatment regimens (see Table 2).
In another meta-analysis,26 data from the PIONEER AF-PCI, RE-
DUAL PCI, and AUGUSTUS trials were evaluated. The use of DOACs 
was associated with significantly lower rates of bleeding and similar 
rates of ischemic events (stroke, MI, and stent thrombosis) and all-
cause death/cardiovascular mortality than VKA-based treatments 
(Table 3). Dual antithrombotic therapy was associated with a signifi-
cantly lower incidence of bleeding; similar rates of stroke, MI, and 
all-cause/cardiovascular death; and a significantly greater risk of 
stent thrombosis when compared with TT (Table 3).
Overall, available data support the use of full-dose DOAC (dab-
igatran 150 mg twice daily or apixaban 5 mg twice daily) or rivarox-
aban 15 mg once daily in patients with AF and ACS or PCI. An initial 
course of first months after ACS or PCI may be prudent, particularly 
in patients at high risk of recurrent ischemia.
Outcomes
VKA + DAPT (reference)
VKA + P2Y12 
inhibitor DOAC + DAPT
DOAC + P2Y12 
inhibitor
HR 95% CI HR 95% CI HR 95% CI
TIMI major bleeding 0.58 0.31-1.08 0.70 0.38-1.23 0.49 0.30-0.82
TIMI major and minor bleeding 0.49 0.26-0.92 0.63 0.33-1.17 0.43 0.25-0.76
Primary safety outcome (trial 
defined)
0.45 0.21-0.92 0.64 0.31-1.31 0.47 0.25-0.85
ICH 1.44 0.40-5.22 0.54 0.15-1.92 0.26 0.08-0.79
All-cause death 0.84 0.40-1.56 1.04 0.54-1.98 1.02 0.59-1.74
Cardiovascular death 0.82 0.42-1.49 0.94 0.53-1.63 1.11 0.70-1.75
Primary MACE (trial defined) 0.96 0.60-1.46 0.94 0.60-1.15 1.02 0.71-1.97
MI 1.25 0.77-1.99 1.13 0.72-1.78 1.18 0.81-1.72
Stroke 1.02 0.36-2.65 0.91 0.35-2.32 0.77 0.34-1.67
Stent thrombosis 1.08 0.46-2.31 0.93 0.40-2.17 1.41 0.71-2.76
Hospitalization 0.86 0.57-1.23 0.80 0.55-1.13 0.80 0.59-1.08
Note: Odds ratio < 1 favors nonreference strategy; odds ratio > 1 favors reference strategy.
Abbreviations: CI, confidence interval; DAPT, dual antiplatelet therapy; DOAC, direct oral 
anticoagulants; ICH, intracranial hemorrhage; MACE, major adverse cardiac event; MI, myocardial 
infarction; OR, odds ratio; TIMI, Thrombolysis in Myocardial Infarction; VKA, vitamin K antagonist.
TA B L E  2   Summarized outcomes of 
trials assessing treatment regimens in 
patients with AF with ACS or PCI/stenting 
25
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3  | TT IN PATIENTS WITH AF AND 
ACS FROM DISCHARGE TO 12 MONTHS 
AFTER ACS
Owing to increased stroke risk in patients with ACS and AF, such 
patients should be considered for concomitant OAC use.27 There is 
no single strategy of TT use that would be suitable for all patients 
with AF and ACS. The composition and duration of TT should be in-
dividualized based on the estimated bleeding and cardioembolic and 
atherothrombotic risks in each patient.28‒32 Stroke risk should be 
evaluated using the CHA2DS2-VASc (congestive heart failure, hyper-
tension, age ≥75 years, diabetes, stroke/transient ischemic attack, 
vascular disease, age 65-74 years, sex category) score, while the risk 
of ischemic events risk can be determined using the Global Registry 
of Acute Coronary Events (GRACE) score.29 The risk of bleeding risk 
is dynamic and should be regularly reassessed using the HAS-BLED 
(hypertension, abnormal renal/liver function, stroke, bleeding history 
or predisposition, labile INR) score. Modifiable bleeding risk factors 
should be identified and actively managed.28,33,34 Of note, the use of 
a formal bleeding risk score has been shown to be superior to rely-
ing only on an approach based on modifiable bleeding risk factors.35
4  | BLEEDING PREVENTION AND 
BLEEDING REDUCTION STRATEGIES
TT is associated with increased rates of major bleeding ranging from 
5% to 15% at 1 year.36‒40 Unfortunately, major bleeding may result 
in a 2- to 8-fold increase in the risk of mortality and nonfatal cardio-
vascular events.41‒45
The risk of bleeding varies with different antithrombotic 
treatment regimens. The risk of bleeding with aspirin together 
with clopidogrel is higher during the early months after initiation. 
Bleeding on warfarin is also highest in the early period after the drug 
initiation (initial 3 months).46 Clinical risk scores may facilitate de-
cision making regarding the most suitable treatment strategy, but 
their predictive ability is generally modest, and interscore variability 
is present.47 Another hurdle is that bleeding risk is closely related to 
the stroke risk and some thromboembolic risk factors such as older 
age, uncontrolled hypertension, or history of stroke have also been 
identified as bleeding risk factors.48 Thus, patients with high bleed-
ing risk also have a high risk of stroke.
To minimize bleeding risk, while maintaining antithrombotic ef-
fect,49 VKA therapy should be well managed, with a high TTR (>65%-
70%),50 and the lowest effective dose of aspirin should be chosen. 
Regarding DOACs, the doses approved for stroke prevention should 
be used. Data on concomitant use of prasugrel or ticagrelor in patients 
taking OACs are scarce, and the risk of bleeding with either of these 
drugs may be excessive in combination with aspirin in anticoagulated 
patients.31,51,52 Hence, clopidogrel is the preferred antiplatelet agent 
regarding PCI in patients with indications for OACs.9,28,53 Importantly, 
new-generation drug-eluting stents and radial approach should be 
used to minimize bleeding risk, while proton pump inhibitors should 
be considered in all patients receiving TT to minimize gastrointestinal 
bleeding.51 Concomitant use of nonsteroidal anti-inflammatory drugs 
should be avoided in patients with AF and ACS (Figure 2).49
5  | CHALLENGES IN COMBINED 
ANTITHROMBOTIC AND 
ANTIPLATELET THERAPY
One of the most challenging patients among AF population are those 
with AF and end-stage renal disease on hemodialysis. Severe chronic 
kidney disease (CKD) elevates the risk of major and intracranial bleed-
ing, and this risk may be greater by the use of OAC or/and antiplatelet 
therapy. The evidence for antithrombotic therapy declines with the 
renal function.54 There are no randomized trials dedicated to OACs 
in patients undergoing hemodialysis. Of note, there are currently 3 
TA B L E  3   Summarized outcomes of PIONEER-PCI, RE-DUAL 
PCI, and AUGUSTUS trials26
Outcomes
Dual antithrombotic 
therapy versus triple 
antithrombotic 
therapy
DOAC-based 
antithrombotic 
treatment regimen 
versus VKA-based 
antithrombotic 
treatment regimen
OR 95% CI OR 95% CI
ISTH major 
bleeding
0.60 0.49-0.73 0.58 0.48-0.70
Stroke 1.01 0.68-1.51 0.84 0.56-1.28
Myocardial 
infarction
1.21 0.96-1.54 0.98 0.78-1.25
Stent thrombosis 1.67 1.02-2.73 1.10 0.68-1.77
All-cause death 1.05 0.83-1.34 1.02 0.80-1.30
CV death 1.13 0.81-1.56 1.11 0.80-1.55
Abbreviations: CI, confidence interval; CV; cardiovascular; DOAC, 
direct oral anticoagulant; OR, odds ratio; VKA, vitamin K antagonist.
F I G U R E  2   Strategies to reduce bleeding risk. DAPT, dual 
antiplatelet therapy; DES, drug-eluting stent; INR, International 
Normalized ratio; NSAID, nonsteroidal anti-inflammatory drug; PPI, 
proton pump inhibitor; VKA, vitamin K antagonist
Consider bleeding risk scores
Use lowest effective dose of aspirin
Optimize DAPT duration
New-generation DES, radial access
Clopidogrel preferential to 
prasugrel or ticagrelor
Optimize anticoagulation with 
VKA (INR 2.0-2.5)
Use PPI and avoid NSAID
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ongoing randomized trials of stroke prevention in patients with AF on 
hemodialysis: the AXADIA trial,55 comparing apixaban 2.5 mg twice 
daily to phenprocoumon; the AVKDIAL trial (Oral Anticoagulation in 
Hemodialysis Patients), comparing VKA to no antithrombotic treat-
ment; and the RENAL-AF (Renal Hemodialysis Patients Allocated 
Apixaban Versus Warfarin in Atrial Fibrillation) trial, comparing 
apixaban 5 mg twice daily to warfarin. In one systematic review and 
meta-analysis56 of 14 observational studies, the use of warfarin in 
patients with AF on hemodialysis was not associated with ischemic 
stroke or ICH. The use of warfarin in the above-mentioned popu-
lation of patients was not associated with a clear benefit or harm. 
In individuals with CKD who start an OAC, concomitant antiplatelet 
therapy including low-dose aspirin may substantially make bleeding 
risk higher and should be used judiciously. In dialysis-dependent pa-
tients, individualized decision making may be appropriate.
6  | FUTURE DIRECTIONS
Many questions regarding optimal combination(s) of antiplatelet and 
antithrombotic therapy in patients with AF and ACS or elective PCI 
remain unanswered, including optimal timing of aspirin cessation and 
adequate P2Y12 inhibitor(s) to be used concomitantly with OACs.
57 
The role of aspirin instead of a P2Y12 inhibitor in dual therapy in dif-
ferent clinical settings also needs further research, as well as the time 
trends in recurrent coronary ischemic events with dual therapy versus 
TT and risk difference with dual therapy versus TT in different clinical 
settings (ie, ACS vs elective PCI, etc). New large-scale randomized 
clinical trials investigating these issues are unlikely, but patient-level 
meta-analyses of available studies could provide additional insights.
Also, the search for efficacious anticoagulant(s) associated with 
minimal bleeding risk continues. Research on anticoagulant agents 
targeting factor XI or XII in the coagulation cascade are promising 
developments.57‒60 Evolutions in antithrombotic therapies for ACS 
are also apparent.7
7  | CONCLUSIONS
Balancing the prevention of stroke and recurrent coronary ischemic 
events against the risk of bleeding in patients with AF and ACS or 
elective PCI may be challenging. To mitigate the risk of bleeding in 
these patients, DOAC-based treatment strategies should be used 
in preference to VKA in DOAC-eligible patients, and duration of TT 
should be minimized. For many patients, a DOAC plus P2Y12 inhibi-
tor early after ACS and/or PCI would be optimal, whereas a longer 
course of TT should be used in patients at high thrombotic risk.
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At the ISTH Congress in Melbourne, there was much focus on AF 
risk assessment and aspects of its management.
For example, Osman61 reported that machine learning algo-
rithms had a good performance in predicting stroke outcomes 
(among others, type of stroke, 1-year survival, and post-stroke de-
pression). Abdulrehman et al62 evaluated the real-world use and 
appropriateness of idarucizumab, which appeared to be in con-
cordance to institutional criteria, mostly for trauma-related hem-
orrhages without knowledge of dabigatran concentration. Costa 
et al63 assessed the effect of a patient-oriented educational strat-
egy focused on low-income patients with poor anticoagulation con-
trol. Patients with AF on warfarin for at least 6 months and with 
TTR <60% were enrolled and the intervention group participated 
in educational sessions based on a patient-oriented care approach, 
which seem to improve anticoagulation management compared to 
the control group.
In the Effect of Bleeding Risk and Frailty Status on 
Anticoagulation Patterns in Octogenarians With Atrial Fibrillation 
(FRAIL-AF) study, Joosten et al64 examined whether switching from 
INR-guided VKA therapy to a DOAC-based management strategy 
compared to continuing VKA therapy was safe in frail elderly pa-
tients with AF.
Foulon et al65 evaluated the link between plasma dabigatran con-
centrations and thrombinography/fibrinography parameters mea-
sured using the thrombodynamics system in an in vitro study and in 
18 subjects aged >80 years receiving dabigatran for AF. They found 
that thrombodynamics enables a reliable analysis of the concentra-
tion-dependent effect of dabigatran on thrombinography and some 
fibrinography parameters.
Douketis et al66 reported that in dabigatran and rivarox-
aban-medicated patients who interrupted therapy for an elective 
surgery/procedure, DOAC level cannot be reliably determined 
by a normal prothrombin time or an activated partial thrombo-
plastin time. In apixaban-medicated patients, an undetectable/
minimal DOAC level might be reported based on a normal throm-
bin time.
Konigsbrugge et al67 evaluated the risk of major bleeding in he-
modialyzed patients associated with antithrombotic treatment (the 
Vienna Investigation of Atrial fibrillation and Thromboembolism in 
Hemodialysis Patients [VIVALDI]). The incidence of major bleed-
ings was greater in individuals on hemodialysis and the risk of major 
bleeding was equally elevated in patients on anticoagulation and an-
tiplatelet drugs.
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